Beta-adrenergic receptor polymorphism in human cardiovascular disease

Area of Science:

• Pharmacogenetics
• Molecular Biology
• Cardiovascular Research

Background:

• Beta-adrenoceptors (beta1 and beta2) possess common genetic variations (polymorphisms).
• Specific polymorphisms, such as Ser49Gly and Arg389Gly in beta1, and Arg16Gly, Gln27Glu, and Thr164Ile in beta2, are known to affect receptor function.
• In vitro studies indicate differential susceptibility to down-regulation and agonist responsiveness among these variants.

Purpose of the Study:

• To review the functional consequences of common beta-adrenoceptor polymorphisms.
• To assess the in vivo phenotypic relevance of these polymorphisms in human studies.
• To determine the potential role of beta-adrenoceptor polymorphisms in disease etiology and progression.

Main Methods:

• Literature review of in vitro, ex vivo, and in vivo studies.
• Analysis of functional data from agonist-stimulation experiments.
• Evaluation of human studies investigating phenotypic outcomes.

Main Results:

• In vitro studies show Gly49 beta1 and Gly16 beta2 variants are prone to down-regulation.
• The Glu27 beta2 variant appears resistant to down-regulation.
• Arg389 beta1 exhibits enhanced agonist responsiveness, while Ile164 beta2 shows decreased responsiveness in vitro.
• In vivo human studies provide some support for these functional effects, but conclusive evidence is lacking.

Conclusions:

• Beta-adrenoceptor polymorphisms significantly impact receptor function in vitro.
• The in vivo phenotypic consequences of these polymorphisms are not yet fully established.
• These polymorphisms are unlikely to be disease-causing but may act as risk factors or disease modifiers.